Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
250
datasets available to search
ShareScore release 0.9.0
Dataset results
250 results for “line position”
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
ClinicalTrials.gov study NCT03052608. IPD Sharing: YES. Countries: 23. Publications: 11.
Half-Dose Fulvestrant plus Anastrozole as a First-Line Treatment for Hormone Receptor-Positive Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Abstract Objective The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC[HR+]). The objective of this study was to evaluate the cost-effectiveness of F&A in the first-line treatment for PMW-MBC(HR+) in China. Design We constructed a Markov model over a life-time horizon. The clinical outcomes and utility data were obtained from published literature. Cost data were obtained from official Chinese websites. Sensitivity analyses were performed to test result uncertainty. Setting Chinese health care system perspective. Population A hypothetical cohort of adult patients presenting with PMW-MBC(HR+). Interventions F&A compared with full-dose FUL and ANA monotherapy. Main outcome measures The main outcome of this study was the incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY). Results ANA was estimated to have the lowest cost and minimum life years (LYs). The ICER of F&A versus ANA was $15,665.891/QALY with incremental cost and QALY of $12,401.120 and 0.792, respectively, which was less than the willingness-to-pay (WTP) of $29,383/QALY. Compared with F&A, FUL yielded a higher cost and a shorter lifetime; hence, it was identified as a dominated strategy. The univariate sensitivity analysis indicated the price of FUL was the most influential factor in our study. The probability that F&A was cost-effective at a threshold of $29,383/QALY in China was 86.5%. Conclusion F&A is a cost-effective alternative to FUL and ANA monotherapy for the first-line treatment of PMW-MBC(HR+) in China. F&A is a promising first-line treatment for PMW-MBC(HR+), and more research is needed to evaluate the economy of using F&A in other countries.
Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
ClinicalTrials.gov study NCT04681287. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intrav
ClinicalTrials.gov study NCT01810393. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head an
ClinicalTrials.gov study NCT05287113. IPD Sharing: YES. Countries: 14. Publications: 0.
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
ClinicalTrials.gov study NCT04808752. IPD Sharing: NO. Countries: 1. Publications: 1.
Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT03204734. IPD Sharing: NO. Countries: 1. Publications: 1.
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
ClinicalTrials.gov study NCT03425838. IPD Sharing: NO. Countries: 1. Publications: 4.
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
ClinicalTrials.gov study NCT03653546. IPD Sharing: NO. Countries: 4. Publications: 1.
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
ClinicalTrials.gov study NCT02004769. IPD Sharing: YES. Countries: 1. Publications: 4.
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
ClinicalTrials.gov study NCT06217757. IPD Sharing: NO. Countries: 1. Publications: 1.
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT04978753. IPD Sharing: NO. Countries: 1. Publications: 1.
Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2
ClinicalTrials.gov study NCT03007992. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Trastuzumab in Combination With TS-ONE & Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
ClinicalTrials.gov study NCT01228045. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.
ClinicalTrials.gov study NCT03314636. IPD Sharing: NO. Countries: 3. Publications: 1.
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
ClinicalTrials.gov study NCT04895930. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers
ClinicalTrials.gov study NCT01710605. IPD Sharing: Not stated. Countries: 1. Publications: 2.
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting
ClinicalTrials.gov study NCT04391283. IPD Sharing: NO. Countries: 1. Publications: 10.
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
ClinicalTrials.gov study NCT03720873. IPD Sharing: YES. Countries: 1. Publications: 0.
Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
ClinicalTrials.gov study NCT06344780. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.